Literature DB >> 15806276

Arterial injuries from femoral artery cannulation with port access cardiac surgery.

Bart E Muhs1, Aubrey C Galloway, Michael Lombino, Michael Silberstein, Eugene A Grossi, Stephen B Colvin, Patrick Lamparello, Glenn Jacobowitz, Mark A Adelman, Caron Rockman, Paul J Gagne.   

Abstract

Although minimally invasive (MI) cardiac surgery reduces blood loss, hospital stay, and recovery time, some MI approaches require femoral arterial cannulation, which introduces a heretofore unknown risk of femoral arterial injury. This study was performed to examine the risk of femoral arterial injury after Port Access MI cardiac surgery (PA-MICS) with femoral cannulation. Data were prospectively obtained on 739 consecutive patients who had PA-MICS with femoral cannulation between June 1996 and April 2000, identifying any patient with new (<30 days postoperative) arterial insufficiency from the cannulation site. Patient characteristics (gender, age, height, weight, body surface area, smoking, peripheral vascular disease, diabetes) and operative variables (cannula size, cross-clamp time) were examined with univariate and multivariate analysis to identify risk factors for arterial injury. Injuries were defined and classified by radiologic and intraoperative assessment, and follow-up was obtained by patient examination and from the medical records. Femoral arterial occlusion (FAC) occurred in 0.68% (5/739) of patients (4 women, 1 man; age range 26-74 years). The risk of femoral injury was higher in women: 1.31% vs 0.23% (p = 0.07). One patient had intraoperative limb ischemia from iliofemoral dissection and was treated by axillopopliteal bypass. Four patients presented postoperatively with claudication. Three of these had iliofemoral arterial occlusion or localized iliofemoral dissection and were treated with iliofemoral bypass, and 1 patient had localized femoral artery stenosis treated by angioplasty. With a mean follow-up of 17.8 months (range 13-26 months) limb salvage was achieved in all patients. Secondary or tertiary interventions were required in 40% (2/5), both in patients with iliofemoral occlusion, and 1 patient (20% of femoral injuries, 0.135% of overall series) has chronic graft occlusion and long-term claudication. The risk of arterial injury after femoral arterial cannulation and perfusion for Port Access surgery was low (0.68%). This risk is increased in women and is unpredictable. Initial vascular repair has a significant failure rate, and secondary interventions are often necessary. Although the femoral cannulation and perfusion technique is safe overall, the risk must be clearly recognized.

Entities:  

Mesh:

Year:  2005        PMID: 15806276     DOI: 10.1177/153857440503900204

Source DB:  PubMed          Journal:  Vasc Endovascular Surg        ISSN: 1538-5744            Impact factor:   1.089


  4 in total

1.  Alternative peripheral perfusion strategies for safe cardiopulmonary bypass in atrial septal defect closure via a right minithoracotomy approach.

Authors:  Hiroto Kitahara; Kazuma Okamoto; Mikihiko Kudo; Akihiro Yoshitake; Takahito Ito; Kanako Hayashi; Yu Inaba; Yuta Akamatsu; Hideyuki Shimizu
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-12-08

2.  Mid-Term Results of Peripheral Cannulation After Robotic Cardiac Surgery.

Authors:  Onur Sen; Unal Aydin; Ersin Kadirogullari; Muhammed Bayram; Mehmet Karacalilar; Erhan Kutluk; Burak Onan
Journal:  Braz J Cardiovasc Surg       Date:  2018 Sep-Oct

3.  Transauricular intra-arterial and intravenous digital subtraction angiography for abdominal aortic aneurysm imaging in a rabbit model.

Authors:  Yonghua Bi; Zepeng Yu; Ke Xu; Hongshan Zhong; Gang Wu; Xinwei Han
Journal:  Ann Med Surg (Lond)       Date:  2017-05-10

4.  Utility of Ultrasonographic Assessment of Distal Femoral Arterial Flow during Minimally Invasive Valve Surgery.

Authors:  Mitsuharu Hosono; Hiroshi Yasumoto; Shintaro Kuwauchi; Yoshino Mitsunaga; Shinya Kanemoto; Naoki Minato; Kohei Kawazoe
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-06-07       Impact factor: 1.520

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.